ID   DCAF1_HUMAN             Reviewed;        1507 AA.
AC   Q9Y4B6; Q2YD74; Q8TBD9; Q9HCA1; Q9UG37;
DT   15-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2007, sequence version 3.
DT   07-APR-2021, entry version 171.
DE   RecName: Full=DDB1- and CUL4-associated factor 1 {ECO:0000312|HGNC:HGNC:30911};
DE   AltName: Full=HIV-1 Vpr-binding protein;
DE            Short=VprBP;
DE   AltName: Full=Serine/threonine-protein kinase VPRBP;
DE            EC=2.7.11.1;
DE   AltName: Full=Vpr-interacting protein;
GN   Name=DCAF1 {ECO:0000312|HGNC:HGNC:30911}; Synonyms=KIAA0800, RIP, VPRBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9872452; DOI=10.1093/dnares/5.5.277;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XI. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:277-286(1998).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=B-cell, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 107-1507, PROTEIN SEQUENCE OF 1174-1186 AND
RP   1328-1343, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH
RP   HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=11223251; DOI=10.1016/s0378-1119(00)00583-7;
RA   Zhang S., Feng Y., Narayan O., Zhao L.-J.;
RT   "Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein
RT   interaction with a novel human cytoplasmic protein VprBP.";
RL   Gene 263:131-140(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 375-1507.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=8195203;
RA   Zhao L.-J., Mukherjee S., Narayan O.;
RT   "Biochemical mechanism of HIV-I Vpr function. Specific interaction with a
RT   cellular protein.";
RL   J. Biol. Chem. 269:15577-15582(1994).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1000, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   INTERACTION WITH DDB1.
RX   PubMed=16949367; DOI=10.1016/j.molcel.2006.08.010;
RA   Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C.;
RT   "A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is
RT   required for S phase destruction of the replication factor Cdt1.";
RL   Mol. Cell 23:709-721(2006).
RN   [10]
RP   FUNCTION.
RX   PubMed=16964240; DOI=10.1038/nature05175;
RA   Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N.;
RT   "Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase
RT   machinery.";
RL   Nature 443:590-593(2006).
RN   [11]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17314515; DOI=10.4161/cc.6.2.3732;
RA   Le Rouzic E., Belaiedouni N., Estrabaud E., Morel M., Rain J.-C.,
RA   Transy C., Margottin-Goguet F.;
RT   "HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of
RT   the Cul4-DDB1 ubiquitin ligase.";
RL   Cell Cycle 6:182-188(2007).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17620334; DOI=10.1074/jbc.m703955200;
RA   Wen X., Duus K.M., Friedrich T.D., de Noronha C.M.;
RT   "The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a
RT   DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as
RT   an adaptor.";
RL   J. Biol. Chem. 282:27046-27057(2007).
RN   [13]
RP   COMPONENT OF E3 UBIQUITIN-PROTEIN LIGASE COMPLEX, INTERACTION WITH HIV-1
RP   VPR (MICROBIAL INFECTION), AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17626091; DOI=10.1128/jvi.01380-07;
RA   Tan L., Ehrlich E., Yu X.F.;
RT   "DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-
RT   induced G2 arrest.";
RL   J. Virol. 81:10822-10830(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION (MICROBIAL INFECTION), AND
RP   INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=17630831; DOI=10.1371/journal.ppat.0030085;
RA   Belzile J.P., Duisit G., Rougeau N., Mercier J., Finzi A., Cohen E.A.;
RT   "HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4A[VPRBP] E3 ubiquitin
RT   ligase.";
RL   PLoS Pathog. 3:E85-E85(2007).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION), AND COMPONENT OF DDA1-DDB1-VRPBP/DCAF1
RP   COMPLEX.
RX   PubMed=17609381; DOI=10.1073/pnas.0702102104;
RA   Hrecka K., Gierszewska M., Srivastava S., Kozaczkiewicz L., Swanson S.K.,
RA   Florens L., Washburn M.P., Skowronski J.;
RT   "Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate
RT   cell cycle.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:11778-11783(2007).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, COMPONENT OF THE
RP   CUL4A-RBX1-DDB1-VPRBP/DCAF1 COMPLEX, AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17559673; DOI=10.1186/1743-422x-4-57;
RA   DeHart J.L., Zimmerman E.S., Ardon O., Monteiro-Filho C.M., Arganaraz E.R.,
RA   Planelles V.;
RT   "HIV-1 Vpr activates the G2 checkpoint through manipulation of the
RT   ubiquitin proteasome system.";
RL   Virol. J. 4:57-57(2007).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=18524771; DOI=10.1074/jbc.m710298200;
RA   Le Rouzic E., Morel M., Ayinde D., Belaidouni N., Letienne J., Transy C.,
RA   Margottin-Goguet F.;
RT   "Assembly with the Cul4A-DDB1[DCAF1] ubiquitin ligase protects HIV-1 Vpr
RT   from proteasomal degradation.";
RL   J. Biol. Chem. 283:21686-21692(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-895, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [19]
RP   FUNCTION, INTERACTION WITH DDB1, COMPONENT OF THE
RP   CUL4A-RBX1-DDB1-VPRBP/DCAF1 COMPLEX, AND CHROMATIN ASSOCIATION.
RX   PubMed=18606781; DOI=10.1128/mcb.00232-08;
RA   McCall C.M., Miliani de Marval P.L., Chastain P.D. II, Jackson S.C.,
RA   He Y.J., Kotake Y., Cook J.G., Xiong Y.;
RT   "Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40
RT   protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for
RT   DNA replication and embryonic development.";
RL   Mol. Cell. Biol. 28:5621-5633(2008).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH NF2.
RX   PubMed=18332868; DOI=10.1038/onc.2008.44;
RA   Huang J., Chen J.;
RT   "VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for
RT   degradation.";
RL   Oncogene 27:4056-4064(2008).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-2 VPX (MICROBIAL
RP   INFECTION).
RX   PubMed=18464893; DOI=10.1371/journal.ppat.1000059;
RA   Srivastava S., Swanson S.K., Manel N., Florens L., Washburn M.P.,
RA   Skowronski J.;
RT   "Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for
RT   cullin 4 E3 ubiquitin ligase to enable macrophage infection.";
RL   PLoS Pathog. 4:E1000059-E1000059(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-888; SER-895 AND SER-898, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-2 VPX (MICROBIAL
RP   INFECTION).
RX   PubMed=19264781; DOI=10.1128/jvi.00187-09;
RA   Bergamaschi A., Ayinde D., David A., Le Rouzic E., Morel M., Collin G.,
RA   Descamps D., Damond F., Brun-Vezinet F., Nisole S., Margottin-Goguet F.,
RA   Pancino G., Transy C.;
RT   "The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1
RT   DCAF1 ubiquitin ligase to overcome a postentry block in macrophage
RT   infection.";
RL   J. Virol. 83:4854-4860(2009).
RN   [24]
RP   IDENTIFICATION IN THE EDVP COMPLEX, AND FUNCTION.
RX   PubMed=19287380; DOI=10.1038/ncb1848;
RA   Maddika S., Chen J.;
RT   "Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3
RT   ligase.";
RL   Nat. Cell Biol. 11:409-419(2009).
RN   [25]
RP   INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=19838296; DOI=10.1371/journal.pone.0007514;
RA   Jacquot G., Le Rouzic E., Maidou-Peindara P., Maizy M., Lefrere J.J.,
RA   Daneluzzi V., Monteiro-Filho C.M., Hong D., Planelles V.,
RA   Morand-Joubert L., Benichou S.;
RT   "Characterization of the molecular determinants of primary HIV-1 Vpr
RT   proteins: impact of the Q65R and R77Q substitutions on Vpr functions.";
RL   PLoS ONE 4:E7514-E7514(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-895, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH NF2.
RX   PubMed=20178741; DOI=10.1016/j.cell.2010.01.029;
RA   Li W., You L., Cooper J., Schiavon G., Pepe-Caprio A., Zhou L., Ishii R.,
RA   Giovannini M., Hanemann C.O., Long S.B., Erdjument-Bromage H., Zhou P.,
RA   Tempst P., Giancotti F.G.;
RT   "Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase
RT   CRL4(DCAF1) in the nucleus.";
RL   Cell 140:477-490(2010).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH LLGL1 AND LLGL2.
RX   PubMed=20644714; DOI=10.1371/journal.pbio.1000422;
RA   Tamori Y., Bialucha C.U., Tian A.G., Kajita M., Huang Y.C., Norman M.,
RA   Harrison N., Poulton J., Ivanovitch K., Disch L., Liu T., Deng W.M.,
RA   Fujita Y.;
RT   "Involvement of Lgl and Mahjong/VprBP in cell competition.";
RL   PLoS Biol. 8:E1000422-E1000422(2010).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=19923175; DOI=10.1128/jvi.01437-09;
RA   Gramberg T., Sunseri N., Landau N.R.;
RT   "Evidence for an activation domain at the amino terminus of simian
RT   immunodeficiency virus Vpx.";
RL   J. Virol. 84:1387-1396(2010).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1000, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-979, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH TERT.
RX   PubMed=23362280; DOI=10.1074/jbc.m112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [34]
RP   FUNCTION.
RX   PubMed=23063525; DOI=10.1016/j.molcel.2012.09.004;
RA   Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H., Kim I.S.,
RA   Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E., Noh D.Y., Kim K.I.,
RA   Kim K.K., Baek S.H.;
RT   "EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4
RT   E3 ubiquitin ligase complex.";
RL   Mol. Cell 48:572-586(2012).
RN   [35]
RP   FUNCTION, AND INTERACTION WITH HISTONE H3.
RX   PubMed=22184063; DOI=10.1128/mcb.06037-11;
RA   Kim K., Heo K., Choi J., Jackson S., Kim H., Xiong Y., An W.;
RT   "Vpr-binding protein antagonizes p53-mediated transcription via direct
RT   interaction with H3 tail.";
RL   Mol. Cell. Biol. 32:783-796(2012).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-255; SER-828; SER-895;
RP   SER-979 AND SER-1328, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [37]
RP   FUNCTION, CATALYTIC ACTIVITY, INDUCTION, MUTAGENESIS OF LYS-194; ASP-361
RP   AND LYS-363, AND CHARACTERIZATION OF VARIANT PHE-378.
RX   PubMed=24140421; DOI=10.1016/j.molcel.2013.09.017;
RA   Kim K., Kim J.M., Kim J.S., Choi J., Lee Y.S., Neamati N., Song J.S.,
RA   Heo K., An W.;
RT   "VprBP has intrinsic kinase activity targeting histone H2A and represses
RT   gene transcription.";
RL   Mol. Cell 52:459-467(2013).
RN   [38]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 VPR (MICROBIAL
RP   INFECTION).
RX   PubMed=24116224; DOI=10.1371/journal.pone.0077320;
RA   Maudet C., Sourisce A., Dragin L., Lahouassa H., Rain J.C., Bouaziz S.,
RA   Ramirez B.C., Margottin-Goguet F.;
RT   "HIV-1 Vpr Induces the Degradation of ZIP and sZIP, Adaptors of the NuRD
RT   Chromatin Remodeling Complex, by Hijacking DCAF1/VprBP.";
RL   PLoS ONE 8:E77320-E77320(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-202 AND SER-1000, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   INTERACTION WITH ESR1 AND LATS1.
RX   PubMed=28068668; DOI=10.1038/nature20829;
RA   Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S.,
RA   De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A.,
RA   Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P.,
RA   Bonamy G.M., Reddy V.A., Bentires-Alj M.;
RT   "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk
RT   with ERalpha.";
RL   Nature 541:541-545(2017).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.47 ANGSTROMS) OF 1058-1396 IN COMPLEX WITH SAMHD1
RP   AND IMMUNODEFICIENCY VIRUS PROTEIN VPX, FUNCTION (MICROBIAL INFECTION), AND
RP   INTERACTION WITH SAMHD1 AND VIRAL VPX (MICROBIAL INFECTION).
RX   PubMed=24336198; DOI=10.1038/nature12815;
RA   Schwefel D., Groom H.C., Boucherit V.C., Christodoulou E., Walker P.A.,
RA   Stoye J.P., Bishop K.N., Taylor I.A.;
RT   "Structural basis of lentiviral subversion of a cellular protein
RT   degradation pathway.";
RL   Nature 505:234-238(2014).
CC   -!- FUNCTION: Acts both as a substrate recognition component of E3
CC       ubiquitin-protein ligase complexes and as an atypical serine/threonine-
CC       protein kinase, playing key roles in various processes such as cell
CC       cycle, telomerase regulation and histone modification. Probable
CC       substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-
CC       protein ligase complex, named CUL4A-RBX1-DDB1-DCAF1/VPRBP complex,
CC       which mediates ubiquitination and proteasome-dependent degradation of
CC       proteins such as NF2. Involved in the turnover of methylated proteins:
CC       recognizes and binds methylated proteins via its chromo domain, leading
CC       to ubiquitination of target proteins by the RBX1-DDB1-DCAF1/VPRBP
CC       complex (PubMed:23063525). The CUL4A-RBX1-DDB1-DCAF1/VPRBP complex is
CC       also involved in B-cell development: DCAF1 is recruited by RAG1 to
CC       ubiquitinate proteins, leading to limit error-prone repair during V(D)J
CC       recombination. Also part of the EDVP complex, an E3 ligase complex that
CC       mediates ubiquitination of proteins such as TERT, leading to TERT
CC       degradation and telomerase inhibition (PubMed:23362280). Also acts as
CC       an atypical serine/threonine-protein kinase that specifically mediates
CC       phosphorylation of 'Thr-120' of histone H2A (H2AT120ph) in a
CC       nucleosomal context, thereby repressing transcription. H2AT120ph is
CC       present in the regulatory region of many tumor suppresor genes, down-
CC       regulates their transcription and is present at high level in a number
CC       of tumors (PubMed:24140421). Involved in JNK-mediated apoptosis during
CC       cell competition process via its interaction with LLGL1 and LLGL2
CC       (PubMed:20644714). {ECO:0000269|PubMed:16964240,
CC       ECO:0000269|PubMed:17609381, ECO:0000269|PubMed:17630831,
CC       ECO:0000269|PubMed:18332868, ECO:0000269|PubMed:18524771,
CC       ECO:0000269|PubMed:18606781, ECO:0000269|PubMed:19287380,
CC       ECO:0000269|PubMed:20644714, ECO:0000269|PubMed:22184063,
CC       ECO:0000269|PubMed:23063525, ECO:0000269|PubMed:23362280,
CC       ECO:0000269|PubMed:24140421}.
CC   -!- FUNCTION: (Microbial infection) In case of infection by HIV-1 virus, it
CC       is recruited by HIV-1 Vpr in order to hijack the CUL4A-RBX1-DDB1-
CC       DCAF1/VPRBP function leading to arrest the cell cycle in G2 phase, and
CC       also to protect the viral protein from proteasomal degradation by
CC       another E3 ubiquitin ligase. The HIV-1 Vpr protein hijacks the CUL4A-
CC       RBX1-DDB1-DCAF1/VPRBP complex to promote ubiquitination and degradation
CC       of proteins such as TERT and ZIP/ZGPAT. {ECO:0000269|PubMed:17314515,
CC       ECO:0000269|PubMed:17559673, ECO:0000269|PubMed:17609381,
CC       ECO:0000269|PubMed:17620334, ECO:0000269|PubMed:17626091,
CC       ECO:0000269|PubMed:17630831, ECO:0000269|PubMed:18524771,
CC       ECO:0000269|PubMed:24116224}.
CC   -!- FUNCTION: (Microbial infection) In case of infection by HIV-2 virus, it
CC       is recruited by HIV-2 Vpx in order to hijack the CUL4A-RBX1-DDB1-
CC       DCAF1/VPRBP function leading to enhanced efficiency of macrophage
CC       infection and promotion of the replication of cognate primate
CC       lentiviruses in cells of monocyte/macrophage lineage.
CC       {ECO:0000269|PubMed:17314515, ECO:0000269|PubMed:18464893,
CC       ECO:0000269|PubMed:19264781, ECO:0000269|PubMed:19923175,
CC       ECO:0000269|PubMed:24336198}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:24140421};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:24140421};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Component of the DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein
CC       ligase complex, named CUL4A-RBX1-DDB1-DCAF1/VPRBP complex. Interacts
CC       with DDB1; the interaction is direct. Also forms a ternary complex with
CC       DDA1 and DDB1. Interacts with NF2 (via FERM domain). Component of the
CC       EDVP complex, a E3 ligase complex containing DYRK2, EDD/UBR5, DDB1 and
CC       DCAF1. Interacts with DYRK2; the interaction is direct. Interacts with
CC       RAG1; the interaction is direct. Interacts with LLGL1 and LLGL2.
CC       Interacts with histone H3. Interacts with ESR1 and LATS1; probably
CC       recruited by LATS1 to promote ESR1 ubiquitination and ubiquitin-
CC       mediated proteasomal degradation (PubMed:28068668).
CC       {ECO:0000269|PubMed:16949367, ECO:0000269|PubMed:17559673,
CC       ECO:0000269|PubMed:17609381, ECO:0000269|PubMed:17626091,
CC       ECO:0000269|PubMed:18332868, ECO:0000269|PubMed:18606781,
CC       ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:20178741,
CC       ECO:0000269|PubMed:20644714, ECO:0000269|PubMed:22184063,
CC       ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:24336198,
CC       ECO:0000269|PubMed:28068668}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 virus Vpr protein;
CC       the interaction is direct. {ECO:0000269|PubMed:11223251,
CC       ECO:0000269|PubMed:17626091, ECO:0000269|PubMed:17630831,
CC       ECO:0000269|PubMed:19838296, ECO:0000269|PubMed:24116224,
CC       ECO:0000269|PubMed:8195203}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-2 virus Vpx protein;
CC       the interaction is direct and the complex recruits SAMHD1 to promote
CC       its ubiquitin-dependent proteasomal degradation.
CC       {ECO:0000269|PubMed:18464893, ECO:0000269|PubMed:19264781,
CC       ECO:0000269|PubMed:24336198}.
CC   -!- INTERACTION:
CC       Q9Y4B6; Q16531: DDB1; NbExp=3; IntAct=EBI-1996353, EBI-350322;
CC       Q9Y4B6; O95835: LATS1; NbExp=4; IntAct=EBI-1996353, EBI-444209;
CC       Q9Y4B6; Q9NRM7: LATS2; NbExp=2; IntAct=EBI-1996353, EBI-3506895;
CC       Q9Y4B6; A0A0H3LAC5: ERDMAN_2289; Xeno; NbExp=2; IntAct=EBI-1996353, EBI-25401874;
CC       Q9Y4B6; P12520: vpr; Xeno; NbExp=5; IntAct=EBI-1996353, EBI-6164519;
CC       Q9Y4B6; P18045: vpx; Xeno; NbExp=2; IntAct=EBI-1996353, EBI-6558105;
CC       Q9Y4B6; P19508: vpx; Xeno; NbExp=4; IntAct=EBI-1996353, EBI-6558117;
CC       Q9Y4B6-3; Q16531: DDB1; NbExp=2; IntAct=EBI-9915372, EBI-350322;
CC       Q9Y4B6-3; P60891: PRPS1; NbExp=3; IntAct=EBI-9915372, EBI-749195;
CC       Q9Y4B6-3; P05928: vpr; Xeno; NbExp=2; IntAct=EBI-9915372, EBI-9210238;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Associated with
CC       chromatin in a DDB1-independent and cell cycle-dependent manner:
CC       recruited to chromatin as DNA is being replicated and is released from
CC       chromatin before mitosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9Y4B6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y4B6-2; Sequence=VSP_025498;
CC       Name=3;
CC         IsoId=Q9Y4B6-3; Sequence=VSP_025499;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:11223251}.
CC   -!- INDUCTION: Up-regulated in a number of cancer cell lines (at protein
CC       level). {ECO:0000269|PubMed:24140421}.
CC   -!- DOMAIN: The protein kinase-like region mediates the threonine-protein
CC       kinase activity. {ECO:0000269|PubMed:24140421}.
CC   -!- DOMAIN: The DWD boxes are required for interaction with DDB1.
CC   -!- DOMAIN: The chromo domain with a restricted pocket directly recognizes
CC       monomethylated substrates. {ECO:0000269|PubMed:23063525}.
CC   -!- SIMILARITY: Belongs to the VPRBP/DCAF1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA34520.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB018343; BAA34520.2; ALT_INIT; mRNA.
DR   EMBL; AC092037; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022792; AAH22792.1; -; mRNA.
DR   EMBL; BC110371; AAI10372.1; -; mRNA.
DR   EMBL; AL080145; CAB45738.1; -; mRNA.
DR   EMBL; AF061935; AAG27134.1; -; mRNA.
DR   CCDS; CCDS74943.1; -. [Q9Y4B6-1]
DR   CCDS; CCDS74944.1; -. [Q9Y4B6-2]
DR   PIR; T12529; T12529.
DR   RefSeq; NP_001165375.1; NM_001171904.1. [Q9Y4B6-2]
DR   RefSeq; NP_055518.1; NM_014703.2. [Q9Y4B6-1]
DR   RefSeq; XP_005276810.1; XM_005276753.4. [Q9Y4B6-1]
DR   RefSeq; XP_005276812.1; XM_005276755.4. [Q9Y4B6-1]
DR   RefSeq; XP_011532575.1; XM_011534273.2. [Q9Y4B6-1]
DR   RefSeq; XP_011532576.1; XM_011534274.2.
DR   RefSeq; XP_011532577.1; XM_011534275.2. [Q9Y4B6-1]
DR   RefSeq; XP_011532578.1; XM_011534276.2.
DR   RefSeq; XP_011532579.1; XM_011534277.2.
DR   RefSeq; XP_016863035.1; XM_017007546.1. [Q9Y4B6-1]
DR   RefSeq; XP_016863036.1; XM_017007547.1. [Q9Y4B6-1]
DR   RefSeq; XP_016863037.1; XM_017007548.1.
DR   RefSeq; XP_016863038.1; XM_017007549.1. [Q9Y4B6-1]
DR   RefSeq; XP_016863039.1; XM_017007550.1. [Q9Y4B6-1]
DR   PDB; 3WA0; X-ray; 2.31 A; G/H=1418-1507.
DR   PDB; 4CC9; X-ray; 2.47 A; A=1058-1396.
DR   PDB; 4P7I; X-ray; 2.60 A; C/D=1447-1507.
DR   PDB; 4PXW; X-ray; 1.72 A; A/B=1039-1401.
DR   PDB; 4Z8L; X-ray; 2.60 A; A/D=1057-1396.
DR   PDB; 5AJA; X-ray; 2.65 A; A=1058-1396.
DR   PDB; 5JK7; X-ray; 3.49 A; C/E=1045-1396.
DR   PDB; 6N45; X-ray; 2.64 A; A/B=1475-1507.
DR   PDBsum; 3WA0; -.
DR   PDBsum; 4CC9; -.
DR   PDBsum; 4P7I; -.
DR   PDBsum; 4PXW; -.
DR   PDBsum; 4Z8L; -.
DR   PDBsum; 5AJA; -.
DR   PDBsum; 5JK7; -.
DR   PDBsum; 6N45; -.
DR   SMR; Q9Y4B6; -.
DR   BioGRID; 115079; 162.
DR   CORUM; Q9Y4B6; -.
DR   DIP; DIP-47048N; -.
DR   IntAct; Q9Y4B6; 75.
DR   MINT; Q9Y4B6; -.
DR   STRING; 9606.ENSP00000393183; -.
DR   iPTMnet; Q9Y4B6; -.
DR   PhosphoSitePlus; Q9Y4B6; -.
DR   BioMuta; DCAF1; -.
DR   DMDM; 147742890; -.
DR   EPD; Q9Y4B6; -.
DR   jPOST; Q9Y4B6; -.
DR   MassIVE; Q9Y4B6; -.
DR   PaxDb; Q9Y4B6; -.
DR   PeptideAtlas; Q9Y4B6; -.
DR   PRIDE; Q9Y4B6; -.
DR   ProteomicsDB; 86151; -. [Q9Y4B6-1]
DR   ProteomicsDB; 86152; -. [Q9Y4B6-2]
DR   ProteomicsDB; 86153; -. [Q9Y4B6-3]
DR   Antibodypedia; 31017; 121 antibodies.
DR   Ensembl; ENST00000335891; ENSP00000338857; ENSG00000145041. [Q9Y4B6-3]
DR   Ensembl; ENST00000423656; ENSP00000393183; ENSG00000145041. [Q9Y4B6-1]
DR   Ensembl; ENST00000504652; ENSP00000421724; ENSG00000145041. [Q9Y4B6-2]
DR   GeneID; 9730; -.
DR   KEGG; hsa:9730; -.
DR   UCSC; uc032rnn.1; human. [Q9Y4B6-1]
DR   CTD; 9730; -.
DR   DisGeNET; 9730; -.
DR   GeneCards; DCAF1; -.
DR   HGNC; HGNC:30911; DCAF1.
DR   HPA; ENSG00000145041; Low tissue specificity.
DR   neXtProt; NX_Q9Y4B6; -.
DR   OpenTargets; ENSG00000145041; -.
DR   PharmGKB; PA142670621; -.
DR   VEuPathDB; HostDB:ENSG00000145041.15; -.
DR   eggNOG; KOG1832; Eukaryota.
DR   GeneTree; ENSGT00390000005874; -.
DR   HOGENOM; CLU_001785_1_0_1; -.
DR   InParanoid; Q9Y4B6; -.
DR   OMA; VWESVCS; -.
DR   OrthoDB; 105679at2759; -.
DR   PhylomeDB; Q9Y4B6; -.
DR   PathwayCommons; Q9Y4B6; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 9730; 40 hits in 204 CRISPR screens.
DR   ChiTaRS; DCAF1; human.
DR   GeneWiki; VPRBP; -.
DR   GenomeRNAi; 9730; -.
DR   Pharos; Q9Y4B6; Tbio.
DR   PRO; PR:Q9Y4B6; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9Y4B6; protein.
DR   Bgee; ENSG00000145041; Expressed in sperm and 222 other tissues.
DR   Genevisible; Q9Y4B6; HS.
DR   GO; GO:0080008; C:Cul4-RING E3 ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:UniProtKB.
DR   GO; GO:1990244; F:histone kinase activity (H2A-T120 specific); IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0106311; F:protein threonine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0035212; P:cell competition in a multicellular organism; IMP:UniProtKB.
DR   GO; GO:1990245; P:histone H2A-T120 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0033151; P:V(D)J recombination; ISS:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR006594; LisH.
DR   InterPro; IPR033270; VPRBP/DCAF1.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR13129; PTHR13129; 1.
DR   SMART; SM00667; LisH; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS50896; LISH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Chromatin regulator; Cytoplasm; Direct protein sequencing;
KW   Host-virus interaction; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation pathway; WD repeat.
FT   CHAIN           1..1507
FT                   /note="DDB1- and CUL4-associated factor 1"
FT                   /id="PRO_0000287473"
FT   DOMAIN          562..593
FT                   /note="Chromo"
FT   DOMAIN          846..878
FT                   /note="LisH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00126"
FT   REPEAT          1091..1130
FT                   /note="WD 1"
FT   REPEAT          1133..1174
FT                   /note="WD 2"
FT   REPEAT          1176..1213
FT                   /note="WD 3"
FT   REPEAT          1215..1247
FT                   /note="WD 4"
FT   REPEAT          1248..1290
FT                   /note="WD 5"
FT   REGION          141..500
FT                   /note="Protein kinase-like"
FT   REGION          1091..1290
FT                   /note="WD repeat-like region"
FT   REGION          1418..1507
FT                   /note="Interaction with NF2"
FT   MOTIF           1242..1249
FT                   /note="DWD box 1"
FT   MOTIF           1278..1285
FT                   /note="DWD box 2"
FT   COMPBIAS        1396..1500
FT                   /note="Asp/Glu-rich (acidic)"
FT   MOD_RES         202
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         255
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         701
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80TR8"
FT   MOD_RES         828
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         888
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         895
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         898
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         979
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1000
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         87
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_025498"
FT   VAR_SEQ         225..673
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_025499"
FT   VARIANT         267
FT                   /note="N -> D (in dbSNP:rs3749318)"
FT                   /id="VAR_051486"
FT   VARIANT         378
FT                   /note="L -> F (does not affect serine/threonine-protein
FT                   kinase kinase activity; dbSNP:rs17712228)"
FT                   /evidence="ECO:0000269|PubMed:24140421"
FT                   /id="VAR_051487"
FT   VARIANT         1031
FT                   /note="L -> P (in dbSNP:rs9835229)"
FT                   /id="VAR_051488"
FT   MUTAGEN         194
FT                   /note="K->R: Abolishes serine/threonine-protein kinase
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:24140421"
FT   MUTAGEN         361
FT                   /note="D->A: Abolishes serine/threonine-protein kinase
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:24140421"
FT   MUTAGEN         363
FT                   /note="K->A: Abolishes serine/threonine-protein kinase
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:24140421"
FT   HELIX           1050..1057
FT                   /evidence="ECO:0007744|PDB:5JK7"
FT   STRAND          1062..1067
FT                   /evidence="ECO:0007744|PDB:5JK7"
FT   HELIX           1076..1078
FT                   /evidence="ECO:0007744|PDB:4CC9"
FT   STRAND          1081..1087
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1096..1101
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1107..1112
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1115..1121
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1122..1124
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1127..1132
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1140..1143
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1147..1153
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1158..1165
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1167..1169
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1171..1176
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1180..1184
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1186..1188
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1191..1196
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1199..1204
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1205..1207
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1210..1214
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1217..1219
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1234..1239
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1242..1245
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1246..1249
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1250..1254
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1259..1262
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1270..1275
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1278..1281
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1282..1284
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1287..1290
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   HELIX           1292..1294
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1297..1301
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1305..1313
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1329..1338
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1339..1341
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1344..1349
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1351..1359
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1361..1363
FT                   /evidence="ECO:0007744|PDB:4CC9"
FT   STRAND          1365..1371
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   TURN            1375..1378
FT                   /evidence="ECO:0007744|PDB:4CC9"
FT   STRAND          1382..1388
FT                   /evidence="ECO:0007744|PDB:4PXW"
FT   STRAND          1482..1485
FT                   /evidence="ECO:0007744|PDB:3WA0"
FT   STRAND          1501..1504
FT                   /evidence="ECO:0007744|PDB:3WA0"
SQ   SEQUENCE   1507 AA;  169007 MW;  7E71AB2CAC4962C5 CRC64;
     MTTVVVHVDS KAELTTLLEQ WEKEHGSGQD MVPILTRMSQ LIEKETEEYR KGDPDPFDDR
     HPGRADPECM LGHLLRILFK NDDFMNALVN AYVMTSREPP LNTAACRLLL DIMPGLETAV
     VFQEKEGIVE NLFKWAREAD QPLRTYSTGL LGGAMENQDI AANYRDENSQ LVAIVLRRLR
     ELQLQEVALR QENKRPSPRK LSSEPLLPLD EEAVDMDYGD MAVDVVDGDQ EEASGDMEIS
     FHLDSGHKTS SRVNSTTKPE DGGLKKNKSA KQGDRENFRK AKQKLGFSSS DPDRMFVELS
     NSSWSEMSPW VIGTNYTLYP MTPAIEQRLI LQYLTPLGEY QELLPIFMQL GSRELMMFYI
     DLKQTNDVLL TFEALKHLAS LLLHNKFATE FVAHGGVQKL LEIPRPSMAA TGVSMCLYYL
     SYNQDAMERV CMHPHNVLSD VVNYTLWLME CSHASGCCHA TMFFSICFSF RAVLELFDRY
     DGLRRLVNLI STLEILNLED QGALLSDDEI FASRQTGKHT CMALRKYFEA HLAIKLEQVK
     QSLQRTEGGI LVHPQPPYKA CSYTHEQIVE MMEFLIEYGP AQLYWEPAEV FLKLSCVQLL
     LQLISIACNW KTYYARNDTV RFALDVLAIL TVVPKIQLQL AESVDVLDEA GSTVSTVGIS
     IILGVAEGEF FIHDAEIQKS ALQIIINCVC GPDNRISSIG KFISGTPRRK LPQNPKSSEH
     TLAKMWNVVQ SNNGIKVLLS LLSIKMPITD ADQIRALACK ALVGLSRSST VRQIISKLPL
     FSSCQIQQLM KEPVLQDKRS DHVKFCKYAA ELIERVSGKP LLIGTDVSLA RLQKADVVAQ
     SRISFPEKEL LLLIRNHLIS KGLGETATVL TKEADLPMTA ASHSSAFTPV TAAASPVSLP
     RTPRIANGIA TRLGSHAAVG ASAPSAPTAH PQPRPPQGPL ALPGPSYAGN SPLIGRISFI
     RERPSPCNGR KIRVLRQKSD HGAYSQSPAI KKQLDRHLPS PPTLDSIITE YLREQHARCK
     NPVATCPPFS LFTPHQCPEP KQRRQAPINF TSRLNRRASF PKYGGVDGGC FDRHLIFSRF
     RPISVFREAN EDESGFTCCA FSARERFLML GTCTGQLKLY NVFSGQEEAS YNCHNSAITH
     LEPSRDGSLL LTSATWSQPL SALWGMKSVF DMKHSFTEDH YVEFSKHSQD RVIGTKGDIA
     HIYDIQTGNK LLTLFNPDLA NNYKRNCATF NPTDDLVLND GVLWDVRSAQ AIHKFDKFNM
     NISGVFHPNG LEVIINTEIW DLRTFHLLHT VPALDQCRVV FNHTGTVMYG AMLQADDEDD
     LMEERMKSPF GSSFRTFNAT DYKPIATIDV KRNIFDLCTD TKDCYLAVIE NQGSMDALNM
     DTVCRLYEVG RQRLAEDEDE EEDQEEEEQE EEDDDEDDDD TDDLDELDTD QLLEAELEED
     DNNENAGEDG DNDFSPSDEE LANLLEEGED GEDEDSDADE EVELILGDTD SSDNSDLEDD
     IILSLNE
//
